Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Цирроз и фиброз печени

Список литературы

  1. Ивашкин В.Т., Маевская М.В., Павлов Ч.С., Федосьина Е.А., Бессонова Е.Н., Пирогова И.Ю., Гарбузенко Д.В. Клинические рекомендации Российского общества по изучению печени и Российской гастроэнтерологической ассоциации по лечению осложнений цирроза печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(4):71-102
  2. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis //J hepatol. – 2018. – Т. 69. – №. 2. – С. 406-460.
  3. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol.- 2010;53:397–417
  4. Angeli P, Garcia-Tsao G, Nadim MK, Parikh RC. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J Hepatol 2019, Vol. 71(4): P811-22
  5. Fasolato S, Angeli P, Dallagnese L, et al. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology 2007;45:223–229.
  6. Guo J, Friedman SL. Hepatic fibrogenesis. Semin Liver Dis 2007; 27: 413-426 
  7. Das SK, Vasudevan DM. Genesis of hepatic fibrosis and its biochemical markers. Scand J Clin Lab Invest 2008; 68: 260-269 
  8. Ramachandran P, Iredale JP. Reversibility of liver fibrosis. Ann Hepatol 2009; 8: 283-291
  9. Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol 2011; 6: 425-456
  10. Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. JHepatol 2015;63:1272–84
  11. Jalan R, Fernandez J, Wiest R, Schnabl B, Moreau R, Angeli P, et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference. J Hepatol 2013;60:1310–1324
  12. Масленников Р.В., Татаркина М.А., Маевская М.В., Павлов Ч.С., Жаркова М.С., Ивашкин В.Т. Влияние синдрома избыточного бактериального роста и системного воспаления на абдоминальную гемодинамику у больных циррозом печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(4):52-61
  13. Claria J, Stauber RE, Coenraad MJ, Moreau R, Jalan R, Pavesi M, et al. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. Hepatology 2016;64:1249–1264
  14. Жаркова М.С. Бактериальная транслокация в патогенезе инфекционных осложнений у больных циррозом печени: автореферат диссертации на соискание ученой степени кандидата медицинских наук. ГБОУ ВПО Первый МГМУ им. И.М. Сеченова, Москва, 2012 г.
  15. Масленников Р.В., Дрига А.А., Ивашкин К.В., Жаркова М.С., Маевская М.В., Павлов Ч.С., Арсланян М.Г., Мусина Н.Б., Березина Е.Н., Ивашкин В.Т. Роль синдрома избыточного бактериального роста и системного воспаления в патогенезе гемодинамических изменений у больных циррозом печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(3):45-56
  16. Ивашкин В.Т., Надинская М.Ю., Буеверов А.О. Печеночная энцефалопатия и методы ее метаболической коррекции. Болезни органов пищеварения 2001;1:25-27
  17. Juan AO, Elizabeth CV. Afferent mechanisms of sodium retention in cirrhosis and hepatorenal syndrome. Kidn Intern, 2010. – Vol. 77(8): PP 669-80.
  18. Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007;133: 481–88.
  19. Национальные клинические рекомендации Минздрава России по лечению кровотечений из варикозно расширенных вен пищевода и желудка. Затевахин И.И., Ивашкин В.Т., Киценко Е.А., Павлов Ч.С., Шерцингер А.Г., Чжао А.В., Маевская М.В., Верткин А.Л., Жигалова С.Б., Огурцов П.П., Бунова С.С., Королев М.П., Котив Б.Н., Дзидзава И.И., Анисимов А.Ю., Прудков М.И., Хоронько Ю.В., Назыров Ф.Г., Девятов А.В., Манукьян Г.В., Лебезев В.М., Цициашвили  М.Ш., Монахов Д.В. Медицинская газета. 2015; (71-74).
  20. Bosch J, Groszmann RJ, Shah VH. Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments. JHepatol 2015;62:S121–S130
  21. De Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol2010; 53: 762-768
  22. D’Amico G, De Franchis R. Upper digestive bleeding in cirrhosis. Posttherapeutic outcome and prognostic indicators. Hepatology 2003;38:599–612
  23. De Franchis RBaveno VI faculty. Expanding consensus in portal hypertension: report of the BAVENO VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. JHepatol 2015;63:743–52
  24. Trawale JM, Paradis V, Rautou PE, Francoz C, Escolano S, Sallee M, et al. The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study. LiverInt 2010;30:725–32
  25. Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol 2015;62:968–74
  26. Krag A, Bendtsen F, Henriksen JH, Moller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut 2010;59:105–110
  27. Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. JHepatol 2014;60:197–209
  28. Van Slambrouck CM, Salem F, Meehan SM, Chang A. Bile cast nephropathy is a common pathologic finding fo kidney injury associated with severe liver dysfunction. KidneyInt 2013;84:192–197
  29. Biggins SW, Rodriguez HJ, Bacchetti P, Bass NM, Roberts JP, Terrault NA. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 2005;41:32–39.
  30. Porcel A, Diaz F, Rendon P, Macias M, Martin-Herrera L, Giron-Gonzalez JA. Dilutional hyponatremia in patients with cirrhosis and ascites. Arch Intern Med 2002;162:323–328.
  31. Piano S, Fasolato S, Salinas F, Romano A, Tonon M, Morando F, et al. The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: Results of a randomized, controlled clinical trial. Hepatology 2016;63:1299–1309.
  32. S. Piano, A. Brocca, S. Mareso, P. Angeli. Infections complicating cirrhosis. Liver Int, 2018,- 38:PP 126-33
  33. Appenrodt B, Grunhage F, Gentemann MG, Thyssen L, Sauerbruch T, Lammert F. Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. Hepatology 2010;51: 1327–33
  34. Badillo R, Rockey DC. Hepatic hydrothorax. Clinical features, management, and outcomes in 77 patients and review of the literature. Medicine 2014;93:135–142.;
  35. Garbuzenko DV, Arefyev NO. Hepatic hydrothorax: An update and review of the literature. World J Hepatol 2017:1197–1204
  36. Rodriguez-Roisin R, Krowka MJ, Herve P, Fallon MB. ERS task force pulmonary-hepatic vascular disorders (PHD) scientific committee. Pulmonary-hepatic vascular disorders (PHD). Eur Respir J 2004;24: 861–880
  37. Machicao VI, Balakrishnan M, Fallon MB. Pulmonary complications in chronic liver disease. Hepatology 2014;59:1627–1637.
  38. Saleemi S. Portopulmonary hypertension. Ann Thorac Med. 2010 Jan-Mar; 5(1): 5–9.
  39. Kaymakoglu S, Kahraman T, Kudat H, Demir K, Cakaloglu Y, Adalet I, et al. Hepatopulmonary syndrome in noncirrhotic portal hypertensive patients. Dig Dis Sci 2003;48:556–560.
  40. Mukomolov S. Hepatitis C in the Russian Federation: сhallenges and future directions / S. Mukomolov, G. Trifonova, I. Levakova, D. Bolsun, E. Krivanogova // Hepatic medicine: evidence and research. – 2016. – Vol. 8. – P. 51–60.
  41. Bajaj JS, Schubert CM, Heuman DM, Wade JB, Gibson DP, Topaz A, et al. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Gastroenterology 2010;138:2332-2340.
  42. Riggio O, Ridola L, Pasquale C, Nardelli S, Pentassuglio I, Moscucci F, et al. Evidence of persistent cognitive impairment after resolution of overt hepatic encephalopathy. Clin Gastroenterol Hepatol 2011;9:181-183.
  43. Zipprich A, Garcia-Tsao G, Rogowski S, Fleig WE, Seufferlein T, Dollinger MM. Prognostic indicators of survival in patients with compensated and decompensated cirrhosis. Liver Int. 2012 Oct;32(9):1407-14.
  44. Romero-Gomez M, Boza F, Garcia-Valdecasas MS, et al. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol 2001;96:2718-2723.
  45. Simonetti  RG, Perricone  G, Robbins  HL, Battula  NR, Weickert  MO, Sutton  R, Khan  S. Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis. Cochrane Database of Systematic Reviews 2020, Issue 10. Art. No.: CD000553.
  46.  Sharma P, Sharma BC, Puri V, Sarin SK. Critical flicker frequency: diagnostic tool for minimal hepatic encephalopathy. J Hepatol 2007;47:67-73.
  47. Bajaj JS. Management options for minimal hepatic encephalopathy. Expert Rev Gastroenterol Hepatol 2008;2:785-90.
  48. Evans LT, Kim WR, Poterucha JJ, Kamath PS. Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites. Hepatology 2003;37:897–901.
  49. Rimola A, Garcia-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 2000;32:142–153.
  50. Arvaniti V, D’Amico G, Fede G, Manousou P, Tsochatzis E, Pleguezuelo M, et al. Infections in patients with cirrhosis increase mortality fourfold and should be used in determining prognosis. Gastroenterology 2010;139:1256.
  51. Шерцингер А.Г. Патогенез, диагностика, профилактика и лечение кровотечений из варикозных вен пищевода и желудка у больных портальной гипертензией: Автореф. дис. …докт. мед. наук. – М. –1986. –310 с.
  52. Жигалова С.Б. Эндоскопические технологии в лечении и профилактике кровотечений из варикозно расширенных вен пищевода и желудка у больных с портальной гипертензией. Автореф. дис. … докт. мед. наук. - М. – 2011. 46 с.
  53. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention and management of gastroesophagealvarices and variceal hemorrhage in cirrhosis. Hepatology 2007; 46, 7: 922-938.
  54. Павлов Ч.С., Дамулин И.В., Ивашкин В.Т. Печеночная энцефалопатия: патогенез, клиника, диагностика, терапия. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(1):44-53.
  55. Patidar KR, Bajaj JS. Covert and overt hepatic encephalopathy: diagnosis and management. Clin Gastroenterol Hepatol. 2015 Nov. 13(12):2048-61.
  56. Fernandez J, Acevedo J, Castro M, Garcia O, de Lope CR, Roca D, et al.; Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 2012;55:1551–1561.
  57.  Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrugresistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268–281.
  58. Gines P., Arroyo V., Rodes J., Schrier R.W. Ascites and renal disfunction in liver disease. Blackwell publishing, 2005.
  59. Soriano G, Castellote J, Alvarez C, Girbau A, Gordillo J, Baliellas C, et al. Secondary bacterial peritonitis in cirrhosis: a retrospective study of clinical and analytical characteristics, diagnosis and management. J Hepatol 2010;52:39–44.
  60. Chen CH, Shih CM, Chou JW, Liu YH, Hang LW, Hsia TC, et al. Outcome predictors of cirrhotic patients with spontaneous bacterial empyema. Liver Int 2011;31:417–24.
  61. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. NephronClinPract 2012;120:c179–c184.
  62. Moreau R, Lebrec D. Diagnosis and treatment of acute renal failure in patients with cirrhosis. Best Pract Res Clin Gastroenterol 2007;21:111–123.
  63. Moreau R, Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. Hepatology 2003;37:233–43.
  64. Луньков В.Д., Маевская М.В., Цветаева Е.К., Мендез А.Г., Жаркова М.С., Ткаченко П.Е., Ивашкин В.Т. Отношение нейтрофилов к лимфоцитам как предиктор неблагоприятного исхода у пациентов с декомпенсированным циррозом печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019;29(1):47-61.
  65. Cordoba J, Garcia-Martinez R, Simon-Talero M. Hyponatremic and hepatic encephalopathies: similarities, differences and coexistence.Metab Brain Dis 2010;25:73–80.
  66. Bloom S., Kemp W., Lubel J. Portal hypertension: pathophysiology, diagnosis and management. Intern Med J. 2015 Jan;45(1):16-26.
  67. Болезни печени и желчевыводящих путей, под ред. В. Т. Ивашкина- 2-е изд., Москва, ООО «Издательский дом «М-Вести», 2005 – 536 с.
  68. Федосьина Е.А., Маевская М.В., Галимова С.Ф.; под ред. Ивашкина В.Т. Лечение осложнений цирроза печени: методические рекомендации для врачей. Российская гастроэнтеролог. Ассоц., РОПИП. – М.: 4ТЕ Арт, 2009.- 60с.
  69. Lin-Lin H, Harry HX, Sen-Lin Z. Ascitic Fluid Analysis in the Differential Diagnosis of Ascites: Focus on Cirrhotic Ascites. J Clin Transl Hepatol, 2014. – Vol.2: 58–64.
  70. Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003;38:258–66.
  71. Bruns T, Lutz P, Stallmach A. Nischalke HD Low ascitic fluid protein does not indicate an increased risk for spontaneous bacterial peritonitis in current cohorts. J Hepatol 2015;63:527–528.
  72. Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med 1992;117:215–220.
  73. Gerbes AL, Jüngst D, Xie YN, Permanetter W, Paumgartner G. Ascitic fluid analysis for the differentiation of malignancy-related and nonmalignant ascites. Proposal of a diagnostic sequence. Cancer 1991;68:1808–14.
  74. McGibbon A, Chen GI, Peltekian KM, van Zanten SV. An evidence-based manual for abdominal paracentesis. Dig Dis Sci. 2007 Dec;52(12):3307-15.
  75. Kimer N, Gluud LL, Morris RW, Morgan MY. Rifaximin for the prevention and treatment of hepatic encephalopathy: A systematic review with meta-analyses of randomised controlled trials. J Clin Exp Hepatol 2017; 7: S78-S79 [DOI: 10.1016/j.jceh.2017.01.105].
  76. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Practice Guidelines Committee of the American Association for the Study of Liver DiseasesPractice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007;46:922–38.
  77. Merli M, Nicolini G, Angeloni S, Rinaldi V, De Santis A, Merkel C, et al. Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol 2003;38:266–272.
  78. Kibrit J, Khan R, Jung BH, Koppe S. Clinical Assessment and Management of Portal Hypertension. Semin Intervent Radiol. 2018, Aug; 35(3): 153-59.
  79. Люсина Е.О. Клиническое применение эластометрии в оценке жизненного прогноза и риска развития осложнений у больных с циррозом печени вирусной (HCV) и алкогольной этиологии. Автореф. дис. …канд. мед. наук. – М. – 2017. 25с.
  80. Weissenborn K, Ennen JC, Schomerus H, Ruckert N, Hecker H. Neuropsychological characterization of hepatic encephalopathy. J Hepatol 2001;34:768-773.
  81. Надинская М.Ю. Латентная печеночная энцефалопатия: как помочь пациенту // Клин. перспективы гастроэнтерол., гепатол. - 2001. - №1. - С.10-17.195.
  82. KangSH, LeeYB, LeeJH, NamJY, ChangY, ChoH, YooJJ, ChoYY, ChoEJ, YuSJ, KimMY, KimYJ, BaikSK, YoonJH. Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy. Aliment Pharmacol Ther. 2017 Nov;46(9):845-855.
  83. Bernardi M, Laffi G, Salvagnini M, Azzena G, Bonato S, Marra F, et al. Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis: a randomized controlled clinical trial comparing two diets with different sodium content. Liver 1993;13:156–62.
  84. Bernardi M, Trevisani F, Gasbarrini A, Gasbarrini G. Hepatorenal disorders: role of the renin-angiotensin-aldosterone system. Semin Liver Dis 1994;14:23–34.
  85. Bernardi M, Servadei D, Trevisani F, Rusticali AG, Gasbarrini G. Importance of plasma aldosterone concentration on the natriuretic effect of spironolactone in patients with liver cirrhosis and ascites. Digestion 1985;31:189–193.
  86. Angeli P, Fasolato S, Mazza E, Okolicsanyi L, Maresio G, Velo E, et al. Combined vs. sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial. Gut 2010;59:98–104.
  87. Guardiola J, Baliellas C, Xiol X, Fernandez Esparrach G, Gines P, Ventura P, et al. External validation of a prognostic model for predicting survival of cirrhotic patients with refractory ascites. Am J Gastroenterol 2002;97:2374–2378.
  88. Lv XY, Ding HG, Zheng JF, Fan CL, Li L. Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study. World J Gastroenterol. 2020 Jan 14;26(2):199-218. doi: 10.3748/wjg.v26.i2.199. PMID: 31988585; PMCID: PMC6962437.
  89. Durand F, Graupera I, Gines P, Olson JC, Nadim MK. Pathogenesis of hepatorenal syndrome: implications for therapy. Am J Kidney Dis 2016;67:318–328.
  90. Albillos A, Banares R, Gonzalez M, Catalina MV, Molinero LM. A metaanalysis of transjugular intrahepatic portosystemic shunt vs. paracentesis for refractory ascites. J Hepatol 2005;43:990–996.
  91. Bai M, Qi XS, Yang ZP, Yang M, Fan DM, Han GH. TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis. World J Gastroenterol 2014;20:2704–2714.
  92. Chen RP, Zhu Ge XJ, Huang ZM, Ye XH, Hu CY, Lu GR, et al. Prophylactic use of transjugular intrahepatic portosystemic shunt aids in the treatment of refractory ascites: metaregression and trial sequential meta-analysis. J Clin Gastroenterol 2014;48:290–299.
  93. Villanueva C, Escorsell A. Optimizing general management of acute variceal bleeding in cirrhosis. Curr Hepatol Rep 2014;13:198–207.
  94. Villanueva C, Colomo A, Bosch A, Concepcion M, Hernandez-Gea V, Aracil C, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013;368:11–21.
  95. Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 2010;362:823–832.
  96. Fernandez J, Ruiz del Arbol L, Gomez C, Durandez R, Serradilla R, Guarner C, et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology 2006;131:1049–1056.
  97. Tandon P, Abraldes JG, Keough A, Bastiampillai R, Jayakumar S, Carbonneau M, et al. Risk of bacterial infection in patients with cirrhosis and acute variceal hemorrhage, based on child-pugh class, and effects of antibiotics. Clin Gastroenterol Hepatol 2015;13:1189–1196.
  98. Altraif I, Handoo FA, Aljumah A, Alalwan A, Dafalla M, Saeed AM, et al. Effect of erythromycin before endoscopy in patients presenting with variceal bleeding: a prospective, randomized, double-blind, placebocontrolled trial. Gastrointest Endosc 2011;73:245–250.
  99. Banares R, Albillos A, Rincon D, Alonso S, Gonzalez M, Ruiz-del-Arbol L, et al. Endoscopic treatment vs. endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology 2002;35:609–615.
  100. García-Pagán JC, Caca K, Bureau C, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010;362: 2370–2379.
  101. Escorsell A, Pavel O, Cardenas A, Morillas R, Llop E, Villanueva C, et al. Esophageal balloon tamponade vs. esophageal stent in controlling acute refractory variceal bleeding: A multicenter randomized, controlled trial. Hepatology 2016;63:1957–1996.
  102. Chau TN, Patch D, Chan YW, Nagral A, Dick R, Burroughs AK. ‘‘Salvage” transjugular intrahepatic portosystemic shunts: gastric fundal compared with esophageal variceal bleeding. Gastroenterology 1998;114:981–998.
  103. Patidar KR, Bajaj JS. Antibiotics for the treatment of hepatic encephalopathy. Metab Brain Dis 2013;28:307-312.
  104. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010;362:1071-81.
  105. Zullo A, Hassan L, Lorenzetti R, Campo MP S, Riggio O. Rifaximin therapy and hepatic encephalopathy: Pros and cons. World J Gastrointest Pharmacol Ther 2012 Aug 6; 3(4): 62–67.
  106. Hudson M, Schuchmann M. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence. Eur J Gastroenterol Hepatol. 2019 Apr; 31(4): 434–450].
  107. Dong Wu, Shu-Mei Wu, Jie Lu, Ying-Qun Zhou, Ling Xu, Chuan-Yong Guo, "Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis", Gastroenterology Research and Practice, vol. 2013, Article ID 236963, 9 pages, 2013.
  108. Kimer N, Krag A, Møller S, Bendtsen F, Gluud LL. Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Ther. 2014 Jul;40(2):123-32.
  109. Butterworth FR, MacPhail JW M. L-Ornithine-L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses. Drugs. 2019; 79(1): 31–37.
  110. Dhiman RK, Thumburu KK, Verma N, Chopra M, Rathi S, Dutta U, Singal AK, Taneja S, Duseja A, Singh M. Comparative Efficacy of Treatment Options for Minimal Hepatic Encephalopathy: A Systematic Review and Network Meta-Analysis. Clin Gastroenterol Hepatol. 2020 Apr;18(4):800-812.e25.
  111. Roger F. Butterworth, Gerald Kircheis y, Norbert Hilger z, Mark J.W. McPhail. Efficacy of L-Ornithine L-Aspartate for the Treatment of Hepatic Encephalopathy and Hyperammonemia in Cirrhosis: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Clinical and Experimental Hepatology | September 2018 | Vol. 8 | No. 3 | 301–313.
  112. Rimola A, Salmeron JM, Clemente G, Rodrigo L, Obrador A, Miranda ML, et al. Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study. Hepatology 1995;21:674–679.
  113. Lutz P, Nischalke HD, Kramer B, Goeser F, Kaczmarek DJ, Schlabe S, et al.; Antibiotic resistance in healthcare-related and nosocomial spontaneous bacterial peritonitis. Eur J Clin Invest 2017;47:44–52.
  114. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N EnglJ Med 1999;341:403–409.
  115. Garioud A, Cadranel JF, Pauwels A, Nousbaum JB, Thévenot T, Dao T, et al. Association Nationale des Hépato-gastroentérologues des Hôpitaux Généraux de France, Association Française pour l’Etude du Foie, Club de Réflexion des Cabinets et Groupes d’Hépato-Gastroentérologie. Albumin Use in Patients With Cirrhosis in France: Results of the ‘‘ALBULIVE” Survey: A Case for Better EASL Guidelines Diffusion and/or Revision. J Clin Gastroenterol 2017;51:831–838.
  116. Merli M, Lucidi C, Di Gregorio V, Lattanzi B, Giannelli V, Giusto M, et al. An empirical broad spectrum antibiotic therapy in health-care-associated infections improves survival in patients with cirrhosis: A randomized trial. Hepatology 2016;63:1632–1639.
  117. Nadim MK, Durand F, Kellum JA, Levitsky J, O’Leary JG, Karvellas CJ, et al. Management of the critically ill patient with cirrhosis: A multidisciplinary perspective. J Hepatol 2016;64:717–735.
  118. Umgelter A, Reindl W, Wagner KS, Franzen M, Stock K, Schmid RM, et al. Effects of plasma expansion with albumin and paracentesis on haemodynamics and kidney function in critically ill cirrhotic patients with tense ascites and hepatorenal syndrome: a prospective uncontrolled trial. Critical care 2008;12:R4.
  119. Gluud LL, Christensen K, Christensen E, Krag A. Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev 2012:CD005162.
  120. Facciorusso A, Chandar AK, Murad MH, Prokop LJ, Muscatiello N, Kamath PS. Singh S. Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 2017;2:94–102.
  121. Rodriguez E, Elia C, Sola E, Barreto R, Graupera I, Andrealli A, et al. Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis. J Hepatol 2014;60:955–961.
  122.  Cavallin M, Kamath PS, Merli M, Fasolato S, Toniutto P, Salerno F, et al. Terlipressin plus albumin vs. midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. Hepatology 2015;62:567–574.
  123. Cavallin M, Piano S, Romano A, Fasolato S, Frigo AC, Benetti G, et al. Terlipressin given by continuous intravenous infusion vs. intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study. Hepatology 2016;63:983–992.
  124. Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichai P, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002;122:923–930.
  125. Narahara Y, Kanazawa H, Taki Y, Kimura Y, Atsukawa M, Katakura T et al. Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis. J Gastroenterol Hepatol 2009;24: 1791–1797.
  126. Garcia-Martinez R, Caraceni P, Bernardi M, Gines P, Arroyo V, Jalan R. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology 2013;58:1836–1846.
  127. Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT, Martini S, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol 2007;47:499–505.
  128. Duvoux C, Zanditenas D, Hezode C, Chauvat A, Monin JL, Roudot-Thoraval F, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 2002;36:374–380.
  129. Singh V, Ghosh S, Singh B, Kumar P, Sharma N, Bhalla A, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol 2012;56:1293–1298.
  130. Sharma P, Kumar A, Shrama BC, Sarin SK. An open label, pilot, randomized controlled trial of noradrenaline vs. terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol 2008;103:1689–1697.
  131. Piano S, Morando F, Fasolato S, Cavallin M, Boscato N, Boccagni P, et al. Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: a new exception to MELD score in the allocation system to liver transplantation? J Hepatol 2011;55:491–496.
  132. Restuccia T, Ortega R, Guevara M, Gines P, Alessandria C, Ozdogan O, et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol 2004;40:140–146.
  133. Rodriguez E, Henrique Pereira G, Sola E, Elia C, Barreto R, Pose E, et al. Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: Effects on kidney function and transplantation outcomes. Liver Transpl 2015;21:1347–1354.
  134. Alonso JC. Pleural effusion in liver disease. Semin Respir Crit Care Med 2010;31:69 –705.
  135. Rodríguez-Roisin R, Krowka MJ. Hepatopulmonary syndrome; a liverinduced lung vascular disorder. N Engl J Med 2008;358: 2378–87.
  136. Tsauo J, Weng N, Ma H, Jiang M, Zhao H, Li X. Role of transjugular intrahepatic portosystemic shunts in the management of hepatopulmonary syndrome: a systemic literature review. J Vasc Interv Radiol 2015;26:1266–1271.
  137. Ditah IC, Al Bawardy BF, Saberi B, Ditah C, Kamath PS. Transjugular intrahepatic portosystemic stent shunt for medically refractory hepatic hydrothorax: A systematic review and cumulative meta-analysis. World J Hepatol 2015;7:1797–1806.
  138. Sauerbruch T, Mengel M, Dollinger M, Zipprich A, Rossle M, Panther E, et al. Prevention of rebleeding from esophageal varices in patients with cirrhosis receiving small-diameter stents vs. hemodynamically controlled medical therapy. Gastroenterology 2015;149:660–668.
  139. Riggio O, Angeloni S, Salvatori FM, De Santis A, Cerini F, Farcomeni A, et al. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene- covered stent grafts. Am J Gastroenterol 2008;103:2738–2746.
  140. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000;31:864–871.
  141. Bureau C, Metivier S, D’Amico M, Peron JM, Otal P, Pagan JC, et al. Serum bilirubin and platelet count: a simple predictive model for survival in patients with refractory ascites treated by TIPS. J Hepatol 2011;54:901–907.
  142. Boyer TD, Sanyal AJ, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, et al. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transpl 2011;17: 1328–1332.
  143. Xiol X, Tremosa G, Castellote J, Gornals J, Lama C, et al. Liver transplantation in patients with hepatic hydrothorax. Transpl Int 2005;18:672–675.
  144. Sersté T, Moreno C, Francoz C, Razek WA, Paugham C, et al. The impact of preoperative hepatic hydrothorax on the outcome of adult liver transplantation. Eur J Gastroenterol Hepatol 2010;22:207–212.
  145. Krowka MJ, Mandell MS, Ramsay MA, Kawut SM, Fallon MB, Manzarbeitia C, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl 2004;10:174–182.
  146. Fallon MB, Krowka MJ, Brown RS, Trotter JF, Zacks S, Roberts KE, et al. Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates. Gastroenterology 2008;135:1168–75.
  147. Маевская М.В., Жаркова М.С. Роль человеческого альбумина в ведении пациентов с циррозом печени. Медицинский Совет. 2020;(5):62-69.
  148. Caraceni P.,Riggio O. Angeli P., Alessandria C., Neri S., Foschi F.G.,et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial The Lancet. 2018;391(10138):2417–2429.
  149. Fernandez J, Tandon P, Mensa J, Garcia-Tsao G. Antibiotic prophylaxis in cirrhosis: Good and bad. Hepatology 2016;63:2019–31.
  150. Soni H, Kumar-M P, Sharma V, Bellam BL, Mishra S, Mahendru D, Mandavdhare HS, Medhi B, Dutta U, Singh V. Antibiotics for prophylaxis of spontaneous bacterial peritonitis: systematic review & Bayesian network meta-analysis. Hepatol Int. 2020 May;14(3):399-413.
  151. Loomba R, Wesley R, Bain A, et al. Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis: meta-analysis. Clin Gastroenterol Hepatol 2009;7:487–493.
  152. Saab S, Hernandez JC, Chi AC, et al. Oral antibiotic prophylaxis reduces spontaneous bacterial peritonitis occurrence and improves short-term survival in cirrhosis: a meta-analysis. Am J Gastroenterol 2009;104: 993–1001.
  153. Min YW, Lim KS, Min BH, Gwak GY, Paik YH, Choi MS, et al. Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: a propensity score matched cohort study. Aliment Pharmacol Ther 2014;40:695–704.
  154. Dam G, Vilstrup H, Watson H, Jepsen P. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites. Hepatology 2016;64: 1265–1272.
  155. Albillos A, Banares R, Gonzalez M, Ripoll C, Gonzalez R, Catalina MV, et al. Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta-analysis. Am J Gastroenterol 2007;102: 1116–26.
  156. Li T, Ke W, Sun P, Chen X, Belgaumkar A, Huang Y, et al. Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis. BMJ Open 2016;6:e010902.
  157. Garcia-Pagan JC, De Gottardi A, Bosch J. Review article: the modern management of portal hypertension–primary and secondary prophylaxis of variceal bleeding in cirrhotic patients. Aliment Pharmacol Ther 2008;28:178–86.
  158. Senzolo M, Cholongitas E, Burra P, Leandro G, Thalheimer U, Patch D, et al. Beta-blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int 2009;29:1189–1193.
  159. Reiberger T, Ferlitsch A, Payer BA, Mandorfer M, Heinisch BB, Hayden H, et al. Non-selective beta-blocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol 2013;58:911–921.
  160. Serste T, Melot C, Francoz C, Durand F, Rautou PE, Valla D, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010;52:1017–1022.
  161. Puente A, Hernandez-Gea V, Graupera I, Roque M, Colomo A, Poca M, et al. Drugs plus ligation to prevent rebleeding in cirrhosis: an updated systematic review. Liver Int 2014;34:823–833.
  162. Bureau C, Thabut D, Oberti F, Dharancy S, Carbonell N, Bouvier A, et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology 2017;152:157–163.
  163. Varakanahalli S, Sharma BC, Srivastava S, Sachdeva S, Dahale AS. Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver: a double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo. Eur J Gastroenterol Hepatol. 2018 Aug;30(8):951-958.
  164. Singh S. et al. Association of liver cirrhosis severity with anemia: does it matter? //Annals of gastroenterology. – 2020. – Т. 33. – №. 3. – С. 272.
  165. Abd-Elsalam S. et al. Correlation of platelets count with endoscopic findings in a cohort of Egyptian patients with liver cirrhosis //Medicine. – 2016. – Т. 95. – №. 23.
  166.  Moreau R. et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis //Gastroenterology. – 2013. – Т. 144. – №. 7. – С. 1426-1437.
  167. Rios R. et al. The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis //Official journal of the American College of Gastroenterology| ACG. – 2005. – Т. 100. – №. 6. – С. 1311-1316.
  168.  Sharma S. K., Aggarwal R. Prediction of large esophageal varices in patients with cirrhosis of the liver using clinical, laboratory and imaging parameters //Journal of gastroenterology and hepatology. – 2007. – Т. 22. – №. 11. – С. 1909-1915.
  169. Lammers W. J. et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study //Gastroenterology. – 2014. – Т. 147. – №. 6. – С. 1338-1349. e5.
  170.  Lee H. A. et al. Direct bilirubin is more valuable than total bilirubin for predicting prognosis in patients with liver cirrhosis //Gut and Liver. – 2021. – Т. 15. – №. 4. – С. 599.
  171.  Poynard T. et al. Prognostic value of total serum bilirubin/γ‐glutamyl transpeptidase ratio in cirrhotic patients //Hepatology. – 1984. – Т. 4. – №. 2. – С. 324-327.
  172.  Agustanti N. et al. Correlation between Serum Albumin and Fasting Blood Glucose Level in Patients with Liver Cirrhosis //The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy. – 2014. – Т. 15. – №. 3. – С. 143-146.
  173.  Mammen E. F. Coagulation abnormalities in liver disease //Hematology/oncology clinics of North America. – 1992. – Т. 6. – №. 6. – С. 1247-1257.
  174. Castera L., Pauwels A., Levy V. G. Prognostic indicators in patients with liver cirrhosis admitted to an intensive care unit //Gastroenterologie clinique et biologique. – 1996. – Т. 20. – №. 3. – С. 263-268.
  175. Violi F. et al. Association between low-grade disseminated intravascular coagulation and endotoxemia in patients with liver cirrhosis //Gastroenterology. – 1995. – Т. 109. – №. 2. – С. 531-539.
  176.  Ariza X. et al. Analysis of a urinary biomarker panel for clinical outcomes assessment in cirrhosis //PloS one. – 2015. – Т. 10. – №. 6. – С. e0128145.
  177.  Jain A. P. et al. Spontaneous bacterial peritonitis in liver cirrhosis with ascites //The Journal of the Association of Physicians of India. – 1999. – Т. 47. – №. 6. – С. 619-621.
  178.  Mostafa M. S. et al. Detection of ascitic fluid infections in patients with liver cirrhosis and ascites //Arab Journal of Gastroenterology. – 2011. – Т. 12. – №. 1. – С. 20-24.
  179. Titó L. et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors //Hepatology. – 1988. – Т. 8. – №. 1. – С. 27-31.
  180. Kudo M. et al. Diagnostic accuracy of imaging for liver cirrhosis compared to histologically proven liver cirrhosis //Intervirology. – 2008. – Т. 51. – №. Suppl. 1. – С. 17-26.
  181.  Primignani M. et al. Natural history of portal hypertensive gastropathy in patients with liver cirrhosis //Gastroenterology. – 2000. – Т. 119. – №. 1. – С. 181-187.
  182. Lin K. H. et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection in patients with liver cirrhosis: a systematic review and meta-analysis //Diagnostic microbiology and infectious disease. – 2014. – Т. 80. – №. 1. – С. 72-78.
  183.  Santos J. et al. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety //Journal of hepatology. – 2003. – Т. 39. – №. 2. – С. 187-192.
  184. Fiaccadori F. et al. Torasemide versus furosemide in cirrhosis: a long-term, double-blind, randomized clinical study //The clinical investigator. – 1993. – Т. 71. – №. 7. – С. 579-584.
  185. Abecasis R. et al. Long-term efficacy of torsemide compared with frusemide in cirrhotic patients with ascites //Scandinavian journal of gastroenterology. – 2001. – Т. 36. – №. 3. – С. 309-313.
  186. Elsabaawy M. M. et al. The impact of paracentesis flow rate in patients with liver cirrhosis on the development of paracentesis induced circulatory dysfunction //Clinical and molecular hepatology. – 2015. – Т. 21. – №. 4. – С. 365.
  187. Salerno F. et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites //Hepatology. – 2004. – Т. 40. – №. 3. – С. 629-635.
  188.  Maimone S. et al. Predictors of re-bleeding and mortality among patients with refractory variceal bleeding undergoing salvage transjugular intrahepatic portosystemic shunt (TIPS) //Digestive diseases and sciences. – 2019. – Т. 64. – №. 5. – С. 1335-1345.
  189.  Noguchi H., Toyonaga A., Tanikawa K. Influence of nitroglycerin on portal pressure and gastric mucosal hemodynamics in patients with cirrhosis //Journal of gastroenterology. – 1994. – Т. 29. – №. 2. – С. 180-188.
  190. Moss O. Nutrition priorities: Diet recommendations in liver cirrhosis //Clinical liver disease. – 2019. – Т. 14. – №. 4. – С. 146.
  191.  Les I. et al. Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study //Official journal of the American College of Gastroenterology| ACG. – 2011. – Т. 106. – №. 6. – С. 1081-1088.
  192. Kadry Z. et al. Excellent Outcomes With Liver Transplantation in Hepatopulmonary Syndrome Across Pre-Transplant PaO2 Spectrum //JHEP Reports. – 2021. – С. 100351.
  193. Ginés P. et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double‐blind, placebo‐controlled trial //Hepatology. – 1990. – Т. 12. – №. 4. – С. 716-724.
  194. Child CG, Turcotte JG. Surgery and portal hypertension. In: The liver and portal hypertension. Edited by CG Child. Philadelphia: Saunders 1964:50-64.
  195. Teasdale G., Jennett B. Assessment of coma and impaired consciousness. A practical scale. (англ.) // The Lancet : journal. — Elsevier, 1974. — Vol. 2, no. 7872. — P. 81—4.
  196. Christidis C. et al. Worsening of hepatic dysfunction as a consequence of repeated hydroxyethylstarch infusions //Journal of hepatology. – 2001. – Т. 35. – №. 6. – С. 726-732.
  197. González-Abraldes J, Albillos A, Banares R et al. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis //Gastroenterology. – 2001. - Vol. 121(2): PP 382-88.
  198. Kim SG. et al. A randomized, multi-center, open-label study to evaluate the efficacy of carvedilol vs. propranolol to reduce portal pressure in patients with liver cirrhosis //Official journal of the American College of Gastroenterology| ACG. – 2016. – Vol. 111 (11): PP 1582-1590.
  199. Bai Y., Guo J. F., Li Z. S. Meta‐analysis: erythromycin before endoscopy for acute upper gastrointestinal bleeding //Alim pharmacol therфз – 2011. Мщдю 34(2): PP 166-171.
  200. Goel A, Rahim U, Nguyen LH et al. Systematic review with meta-analysis: rifaximin for the prophylaxis of spontaneous bacterial peritonitis // Aliment Pharmacol Therap. – 2017. – Vol. 46 (11-12): ЗЗ1029-1036.
  201. Zhang S-H, Zhu Z-Y, Chen Z, Li Y, ZouY, Yan M, Xu Y, Wang F, Liu M-Z, Zhang M,Zhang B-K. 2020. Population pharmacokineticsand dosage optimization of linezolid inpatients with liver dysfunction. AntimicrobAgents Chemother 64:e00133-20.
  202. Kuo C. H. et al. Bacteremia in patients with cirrhosis of the liver //Liver. – 1991. – Т. 11. – №. 6. – С. 334-339.
  203. Han D. et al. Impact of elevated urine leukocyte and bacteria count per high-power field on the in-hospital outcome of patients with liver cirrhosis //Journal of Public Health and Emergency. – 2017. – Т. 1. – С. 73-73.
  204. TrifanA. etal. Clostridium difficile infection in patients with liver disease: a review //European Journal of Clinical Microbiology & Infectious Diseases. – 2015. – Т. 34. – №. 12. – С. 2313-232.
  205. JeongJ. H. etal. CLIF–SOFA score and SIRS are independent prognostic factors in patients with hepatic encephalopathy due to alcoholic liver cirrhosis //Medicine. – 2016. – Т. 95. – №. 26.
  206. Uriz J. et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome //Journal of hepatology. – 2000. – Т. 33. – №. 1. – С. 43-48.
  207. Andersen M. M. et al. Rehabilitation for cirrhotic patients discharged after hepatic encephalopathy improves survival //Dan Med J. – 2013. – Т. 60. – №. 8. – С. A4683.
  208. Schmidt N. P. et al. Nutritional and functional rehabilitation in cirrhotic patients //Journal of Gastroenterology and Hepatology Research. – 2021. – Т. 10. – №. 2. – С. 3470-3477.
  209. Zhang S-H, Zhu Z-Y, Chen Z, Li Y, Zou Y, Yan M, Xu Y, Wang F, Liu M-Z, Zhang M, Zhang B-K. 2020. Population pharmacokinetics and dosage optimization of linezolid in patients with liver dysfunction. Antimicrob Agents Chemother 64:e00133-20.

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*